Applying the UPLC-Zone TOF-MS/MS combined network pharmacology to explore the effects of MFS intervention on NAFLD

HU Tao; WANG Bingyu; SU Weiwei; PENG Wei; LI Jianhua; LI Changqing; ZHOU Yiye; GUO Jiewen

doi:10.13471/j.cnki.acta.snus.ZR20240154

您当前的位置：

首页 >

文章列表页 >

Applying the UPLC-Zone TOF-MS/MS combined network pharmacology to explore the effects of MFS intervention on NAFLD

Research articles | 更新时间：2024-11-07

- Applying the UPLC-Zone TOF-MS/MS combined network pharmacology to explore the effects of MFS intervention on NAFLD
- Acta Scientiarum Naturalium Universitatis Sunyatseni Vol. 63, Issue 5, Pages: 73-82(2024)
- 作者机构：
  
  1.广州医科大学附属中医医院，广东广州 510000
  2.广东省中药上市后质量与药效再评价工程技术研究中心 / 广东省热带亚热带植物资源重点实验室 / 中山大学生命科学学院，广东广州 510275
  3.广州中医药大学青蒿研究中心，广东广州 510006
- 作者简介：
- 基金信息：
- DOI：10.13471/j.cnki.acta.snus.ZR20240154
  CLC： R285.5
- Published：25 September 2024，
  
  Published Online：22 July 2024，
  
  Received：11 May 2024，
  
  Accepted：12 June 2024
- 稿件说明：
移动端阅览
胡涛,王冰钰,苏薇薇等.基于UPLC-Zone TOF-MS/MS联合网络药理学探讨脉复生防治NAFLD作用[J].中山大学学报(自然科学版)(中英文),2024,63(05):73-82.

HU Tao,WANG Bingyu,SU Weiwei,et al.Applying the UPLC-Zone TOF-MS/MS combined network pharmacology to explore the effects of MFS intervention on NAFLD[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2024,63(05):73-82.
胡涛,王冰钰,苏薇薇等.基于UPLC-Zone TOF-MS/MS联合网络药理学探讨脉复生防治NAFLD作用[J].中山大学学报(自然科学版)(中英文),2024,63(05):73-82. DOI： 10.13471/j.cnki.acta.snus.ZR20240154.

HU Tao,WANG Bingyu,SU Weiwei,et al.Applying the UPLC-Zone TOF-MS/MS combined network pharmacology to explore the effects of MFS intervention on NAFLD[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2024,63(05):73-82. DOI： 10.13471/j.cnki.acta.snus.ZR20240154.

摘要

依据脉复生的化学成分，采用网络药理学、分子对接技术、构建NAFLD小鼠模型，探究脉复生防治NAFLD的作用机制。通过UPLC-Zone TOF-MS/MS对脉复生全成分进行检测；借助Swiss生物信息学研究平台获取活性成分和靶点，在OMIM、Disgenet数据库筛选NAFLD疾病靶点，对交集靶点进行PPI分析；在Metascape网站进行GO与KEGG富集分析，对核心靶点与活性成分展开分子对接；采用HFD诱导C57BL/6J小鼠构建NAFLD模型进行核心靶点验证；指认得到130个化学成分，筛选得到54个活性成分与176个可能作用于NAFLD的潜在靶点；根据Degree值对排名前10的成分与靶点进行分子对接实验，对结合能最优的对接模型TNF与Quercetin、IL-17与Asiatic acid、IL-1

与Quercetin进行可视化分析；筛选炎症因子和脂肪代谢相关基因进行qPCR测序。富集分析表明脉复生治疗NAFLD与脂肪酸转化、脂质代谢正向调节等生物过程相关，涉及AGE-RAGE、HIF-1、IL-17等信号通路；与对照组相比，模型组血清学检测ALT、TG、LDL-C指标上升并且HDL-C指标下降（

＜0.05）；与模型组相比，脉复生给药组和辛伐他汀组能够降低小鼠体质量、肝脏和脂肪质量占比（

＜0.05），降低血清中TNF-

、IL-1

和IL-17的含量和mRNA表达，在高剂量时具有显著性差异（

＜0.01）；与对照组相比，脉复生给药组能够通过调节脂质代谢相关基因的表达，降低肝脏脂质堆积，缓解肝脏脂肪变性。

Abstract

The mechanism of MaiFuSheng （MFS） on inhib

iting Nonalcoholic Fatty Liver Disease （NAFLD） were investigated based on the exploration of chemical compositions， the techniques of network pharmacology and molecular docking， and the validation using NAFLD mice model. The components of MFS were identified through UPLC-Zeno TOF-MS/MS. The Swiss Bioinformatics Research Platform were applied to obtain active components and potential targets of MFS. The DisGeNet and OMIM databases were used to screen disease targets of NAFLD. The intersection between disease targets and potential targets of MFS were obtained from Venn diagram， which were analyzed by constructing cross-target protein-protein interaction （PPI） network. The Gene Ontology （GO） and Kyoto Encyclopedia of Genes and Genomes （KEGG） enrichment were conducted on Metascape database. The molecular docking about core targets and active components of MFS were carried out. Using high-fat diet （HFD）-induced C57BL/6J mice as NAFLD animal model to validate key targets. A total of 130 compounds were recognized， 54 active constituents and 176 potential targets of NAFLD were collected. The molecular docking experiments for the top 10 components with the targets are based on the degree value. We found docking models with the best binding energy for TNF-

with Quercetin，IL-17 with Asiatic acid，and IL-1

with Quercetin. We applied qPCR technique to detect above inflammation and lipid metabolism related indicators. Enrichment analysis demonstrated that MFS protects NAFLD via biological processes such as fatty acid transformation and positive regulation of lipid metabolism， as well as signaling pathways such as AGE-RAGE，HIF-1，and IL-17. Compared to the control groups，the model group's ALT，TG，and LDL-C indicators increased，whereas HDL-C indicators dropped（

0.05）. MFS and Simvastatin treatment groups significantly reduced body weight，liver weight，and fat weight compared to the model groups（

0.05）. Higher doses resulted in significant reductions in ser

um levels and expression of TNF-

，IL-1

，and IL-17（

0.01）. Compared to the control groups，the MFS treatment groups can minimize liver lipid accumulation by modulating the expression of lipid metabolism-related genes and improving hepatic fat breakdown.

关键词

UPLC-Zone TOF-MS/MS脉复生非酒精性脂肪肝网络药理学实验验证

Keywords

UPLC-Zone TOF-MS/MSMaiFuShengNAFLDnetwork pharmacologyexperimental validation

references

杜猛，尹红， 2010. 脉复生对脉管炎患者免疫功能的调节作用［J］. 湖北中医杂志， 32（4）： 46-47.

李燕平，沈天然，陈旭，等， 2016. 白介素-17A对胰岛素信号通路的影响及其机制［J］. 中山大学学报（医学科学版）， 37（6）： 809-816.

刘宏，生书晶，苏薇薇， 2018. 复方血栓通胶囊对弥散性血管内凝血模型大鼠肝肾功能的影响［J］. 中山大学学报（自然科学版）， 57（6）：97-102.

刘若轩，李阿荣，邓志军，等， 2018. 脉复生对血栓闭塞性脉管炎大鼠血管内皮炎症的作用［J］. 广东药科大学学报， 34（3）： 330-334.

田爱平，杨永峰， 2023. 非酒精性脂肪性肝病诊断-病理的重要性［J］. 临床肝胆病杂志， 39（3）：491-497.

许磊，汪子铮，牛亦博， 2019. 不同负荷游泳运动对PM2.5暴露运动大鼠肝脏TNF-α、PPAR-γ蛋白表达的影响［J］. 中山大学学报（自然科学版）， 58（6）： 19-24.

钟世顺，李阿荣，洪波，等， 2019. 脉复生加减方对血栓闭塞性脉管炎大鼠血管内皮炎症作用［J］. 今日药学， 29（12）： 804-806.

周伟青，刘若轩，张洁，等，2016. 脉复生对血栓闭塞性脉管炎患者血脂与血液流变学的作用［J］. 广东医学， 37（1）： 130-132.

CHU X， ZHOU Y， ZHANG S， et al， 2022. Chaetomorpha linum polysaccharides alleviate NAFLD in mice by enhancing the PPARα/CPT-1/MCAD signaling［J］. Lipids Health Dis， 21（1）： 140-151.

COTTER G， RINELLA M， 2020. Nonalcoholic fatty liver disease 2020： The state of the disease［J］. Gastroenterology， 158（7）： 1851-1864.

DUAN Y， PAN X， LUO J， et al， 2022. Association of inflammatory cytokines with non-alcoholic fatty liver disease［J］. Front Immunol， 13： 880298.

GONG Z， HAN S， LI C， et al， 2023. Rhinacanthin C ameliorates insulin resistance and lipid accumulation in NAFLD mice via the AMPK/SIRT1 and SREBP-1c/FAS/ACC signaling pathways［J］. Evid Based Complement Alternat Med， 2023： 6603522.

LI J， ZHONG J， HUANG C， et al， 2021. Integration of traditional Chinese medicine and nibble debridement and dressing method reduces thrombosis and inflammatory response in the treatment of thromboangiitis obliterans［J］. Ann Transl Med， 9（18）： 1413.

LIU N， YANG X， GUO J， et al， 2023. Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1-driven gluconeogenesis［J］. EMBO Rep， 24（6）： e56390.

MANTOVANI A， SCORLETTI E， MOSCA A， et al， 2020. Complications， morbidity and mortality of nonalcoholic fatty liver disease［J］. Metabolism， 111： 154170.

MENG Z， LIU X， LI T， et al， 2021. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway［J］. Int Immunopharmacol， 94： 107492.

SHI X， XIONG Y， SONG H， et al， 2024. Progress and hotspot of diet or exercise therapy in the treatment of non-alcoholic fatty liver disease［J］. Front Nutr， 11： 1326092.

SRINIVAS N， SURESH D， SANTHEKADUR K， et al， 2021. Extracellular vesicles as inflammatory drivers in NAFLD［J］. Front Immunol， 11： 627424.

VACHLIOTIS D， POLYZOS A， 2023. The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease［J］. Curr Obes Rep， 12（3）： 191-206.

ZACHOU M， FLEVARI P， NASIRI-ANSARI N， et al， 2024. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail？ A narrative review［J］. Eur J Clin Pharmacol， 80（1）： 127-150.

ZHONG F， ZHOU X， XU J， et al， 2020. Rodent models of nonalcoholic fatty liver disease［J］. Digestion， 101（5）： 522-535.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Exploring the mechanism and function of Xiasangju in the treatment of xerophthalmia based on network pharmacology and experimental validation

Discovery of the active ingredients and the mechanism of action for the effects of Honghe Fujie Lotion on infection based on network pharmacology methods

Network pharmacology analysis of Compound Xueshuantong Capsule （CXC） in improving microcirculation

Related Author

GUO JieWen

PENG Wei

SU Weiwei

WANG BingYu

HU Tao

ZHOU Yiye

LI Changqing

LI Jianhua

Related Institution

Guangzhou University of Chinese Artemisinin Research Center

Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM， Guangdong Key Laboratory of Plant Resources， School of Life Sciences， Sun Yat-sen University

Guangzhou Medical University Affiliated Traditional Chinese Medicine Hospital

Guangdong Engineering and Technology Research Center for Quality and Efficacy Re-evaluation of Post-marketed TCM / Guangdong Key Laboratory of Plant Resources / School of Life Sciences， Sun Yat-sen University

Guangzhou Baiyunshan Xingqun Pharmaceutical Co.， Ltd

Postal code：510275
Tel：020-84112585，84113223 Email：xuebaozr@mail.sysu.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰